Could This Biotech Sacrifice A Buy Point On Drug Safety Questions?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      ALNYLAM Pharmaceuticals Inc. ALNY
    • Abstract:
      The article offers information on the decrease in stock price of Alnylam Pharmaceuticals on March 6, 2019 as investors questioned the drug safety of givosiran. Topics discussed include tested givosiran in patients with acute hepatic porphyria with 10 out of 48 givosiran-treated patients experienced serious side effects; views of Leerink analyst Mani Foroohar on the same; and lowered levels of aminolevuinic acid and porphobilinogen by givosiran.